<DOC>
	<DOCNO>NCT00411268</DOCNO>
	<brief_summary>The purpose open-label , extension study characterize safety , effectiveness , impact quality life measure long-term repeat dose OROS hydromorphone slow release ( 8 , 16 , 32 64 mg tablet ) patient chronic low back pain .</brief_summary>
	<brief_title>Safety , Effectiveness , Impact Quality Life Long-Term Administration OROS Hydromorphone Slow-Release Patients With Chronic Low Back Pain</brief_title>
	<detailed_description>This open label , extension study characterize safety , effectiveness , impact quality life OROS hydromorphone slow release long-term repeat dosing among patient chronic low back pain , previously complete short-term Study DO-127 OROS hydromorphone slow release . Up 150 patient enrol evaluated . Patients enrol study immediately follow Study DO-127 . Patients continue therapy OROS hydromorphone slow release stable dose previously identify short-term study . The patient 's initial prescribed dose OROS hydromorphone slow release Study DO-127X last dose OROS hydromorphone slow release Study DO-127 . Patients return monthly evaluation extension interval . Adjustments dose perform need , Investigator 's discretion . The duration study six month . Safety assessment include vital sign physical examination start , end study . 8 , 16 , 32 64 mg tablet OROS hydromorphone ( dose Investigators ' discretion ) slow release tablet take orally daily duration six month study</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Hydromorphone</mesh_term>
	<criteria>Patients chronic low back pain successfully complete shortterm Study DO127 OROS hydromorphone slow release Patients require least 8 mg hydromorphone HCI ( slow release ) every 24 hour management chronic low back pain Patients whose opioid requirement stable demonstrated shortterm Study DO127 OROS hydromorphone slow release Patients intolerant hypersensitive hydromorphone ( opioid agonist ) Patients pregnant breastfeed Patients gastrointestinal disorder , include preexist severe GI narrowing ( pathologic iatrogenic ) may affect absorption transit orally administer drug Patients significant CNS disorder , include limited head injury , intracranial lesion , increase intracranial pressure , seizure disorder , stroke within past 6 month , disorder cognition , clinically significant impaired renal hepatic function , Addison 's disease , hypothyroidism , prostatic hypertrophy , urethral stricture Patients may risk serious decrease blood pressure upon take opioid analgesic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Chronic low back pain</keyword>
	<keyword>OROS hydromorphone slow release tablet</keyword>
	<keyword>Quality Life</keyword>
</DOC>